Scientists, clinicians, and engineers from around the world gathered at OHSU’s Casey Eye Institute in July for the first international Optical Coherence Tomography (OCT) Angiography Summit. Participants spent the day sharing their knowledge and discussing applications of a pioneering imaging technology that has the potential to transform how we diagnose and treat patients with common causes of blindness, such as macular degeneration, glaucoma, and diabetic retinopathy. James Fujimoto, Ph.D., was the summit’s distinguished guest speaker, … Read More
Posts Tagged ‘Casey Eye Institute’
Researchers at OHSU’s Casey Eye Institute have developed a technology – optical coherence tomography (OCT) angiography – to better diagnose and manage the leading causes of blindness in the U.S. – retinal vascular diseases such as macular degeneration, diabetic eye disease, and glaucoma. According to research published this week in the Proceedings of the National Academy of Sciences, OCT provides a more precise and less invasive alternative to conventional dye-based retinal angiography used for screening and monitoring. OCT … Read More
OHSU Casey Eye Institute researcher David Huang, M.D., Ph.D., is one of six scientists to receive the 2012 António Champalimaud Vision Award, the largest monetary prize for vision research in the world. Dr. Huang was recognized for his role in co-inventing an eye imaging tool called optical coherence tomography (OCT) in the 1990s. Since then, OCT has become the most commonly used imaging tool to test for conditions like macular degeneration and glaucoma. Watch this … Read More
Dr. Justine R. Smith, M.D., Ph.D., has been named the 2012-2013 president-elect of the Association for Research in Vision and Ophthalmology. This is the first time an OHSU physician has held this office since Oregon’s “father of ophthalmology”, Dr. Kenneth C. Swan, was elected to the position in 1951. This is a great accomplishment and honor for Dr. Smith, the Casey Eye Institute and for OHSU as a whole. Congradulations Dr. Smith!
A recent clinical trial involving researchers from OHSU’s Casey Eye Institute comparing two drugs used to treat age-related macular degeneration (AMD) has shown that both Lucentis and Acastin are nearly equally as effective despite the fact that Avastin costs a fraction of what Lucentis costs. These findings were published this week in the medical journal Ophthalmology. A single dose of Lucentis costs approximately $2,000 whereas one dose of Avastin is around $50. Both drugs are … Read More